Tune In Sunday For More On Bristol-Myers’s Cancer Drug
October 05, 2016 at 14:52 PM EDT
It was two months ago that a surprise clinical trial failure of its blockbuster cancer drug Opdivo sent Bristol-Myers Squibb ’s ( BMY ) share price into a tail spin . Well, on Sunday, investors will get a look at more data, this time longer-term data from a separate study call CheckPoint-012 that tested a combination therapy that conjoins Opdivo with the older cancer drug Yervoy on non-small-cell lung cancer
